Machine learning creates opportunity for new personalized therapies

In cell-line and mouse models of ovarian cancer, researchers developed an interdisciplinary approach to identify metabolic vulnerabilities in certain genes that could be targeted to kill cancer cells.

10:27 AM

Author | Anna Megdell

ovarian cancer tumor under microscope lab note
National Cancer Institute

Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.

Cancer mutations occur frequently in ovarian cancer, giving cells a growth advantage that contributes to the aggressiveness of the disease. But sometimes deletions of certain genes can occur alongside these mutations and make cells vulnerable to treatment. Still, cancer cells grow so well because paralog genes can compensate for this loss of function and continue to drive tumor formation.

Deepak Nagrath, Ph.D., associate professor of biomedical engineering who led this study, wanted to understand more about these compensatory genes as they relate to metabolism. "When a gene is deleted, metabolic genes, which allow the cancer cells to grow, are also deleted. The theory is that vulnerabilities emerge in the metabolism of cancer cells due to specific genetic alterations."

When genes that regulate metabolic function are deleted, cancer cells essentially rewire their metabolism to come up with a backup plan. Using a method that integrates complex metabolic modeling, machine learning and optimization theory in cell-line and mouse models, the team discovered an unexpected function of an ovarian cancer enzyme, MTHFD2. This was specific to ovarian cancer cells with an impairment to the mitochondria, due to a commonly occurring deletion of UQCR11. This led to a critical imbalance of an essential metabolite, NAD+, within the mitochondria.

The algorithm predicted that MTHFD2 surprisingly reversed its role to provide NAD+ in the cells. This created a vulnerability that could be targeted to selectively kill off the cancer cells while minimally affecting healthy cells.

"Personalized therapies like this are becoming an increasing possibility for improving efficacy of first-line cancer treatments," said research fellow and first author of this study Abhinav Achreja, Ph.D. "There are several approaches to discovering personalized targets for cancer, and several platforms predict targets based on big data analyses. Our platform makes predictions by considering the metabolic functionality and mechanism, increasing the chances of success when translating to the clinic."

Paper cited: "Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer," Nature Metabolism. DOI: 10.1038/s42255-022-00636-3

This research was supported by funding from the National Cancer Institute, the Office of the Director for the National Institutes of Health, the University of Michigan Precision Health Scholars Award, and Forbes Scholar Award from Forbes Institute of Cancer Discovery.


More Articles About: Lab Notes Ovarian Cancer All Research Topics Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories doctor close up listening to baby's heart while baby touches stethoscope while doctor smiles in doctor exam room on exam room table with medical equipment in background
Health Lab
Commentary: Employers are failing to insure the working class – Medicaid cuts will leave them even more vulnerable
A physician talks about what Medicaid cuts will impact Americans across the country.
breathing tube in patient close up in hospital bed
Health Lab
Removal of ventilator breathing tube is delayed for some patients, posing health risks
A study by Michigan Medicine determined how many patients who pass spontaneous breathing trials were extubated within six hours and what factors were associated with staying connected to a ventilator.
yellow pills spilling out of bottle
Health Lab
Study sheds light on why some prostate tumors are resistant to treatment
A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 
pink cells up close
Health Lab
Research links iron-mediated cell death and inflammatory bowel disease
New basic science insights into programmed cell death could offer relief for inflammatory bowel disease. The University of Michigan study reveals a connection between lipid reactive oxygen species, iron-mediated cell death and IBD.
two foxes on grass
Health Lab
Study reveals mechanisms behind common mutation and prostate cancer
A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.
History map
News Release
From the Diag to the world: 175 years of U-M medical history
An interactive map and article that trace the history of Michigan Medicine